Psoriasis
2 Results
- CommentaryOpen Archive
Does Treatment of Psoriasis Reduce Cardiovascular Comorbidities?
Journal of Investigative DermatologyVol. 137Issue 8p1612–1613Published in issue: August, 2017- Mark Lebwohl
Cited in Scopus: 12Psoriasis has been associated with an increase in myocardial infarctions. Several registries have shown reductions in major adverse cardiovascular events in psoriasis patients and rheumatoid arthritis patients treated with tumor necrosis factor-α antagonists. Many assume that the reduction in cardiovascular events can be attributed to the anti-inflammatory effect of tumor necrosis factor blockers, but a 52-week study conducted by Bissonnette and coworkers failed to show a reduction in cardiovascular inflammation in psoriasis patients treated with adalimumab. - CommentaryOpen Archive
Psoriasis Therapy: Breakthroughs in Pharmacogenomics or in Pharmacology?
Journal of Investigative DermatologyVol. 136Issue 12p2339–2340Published in issue: December, 2016- Mark Lebwohl
Cited in Scopus: 3As the cost of psoriasis therapies skyrockets, it becomes increasingly important to find biomarkers that predict which patients will respond to expensive medications. The ability to predict response to a specific therapy is particularly important for medications that are effective in only a small portion of the population. As we develop medications that clear most patients, the need for a predictive biomarker diminishes. Nevertheless, the importance of pharmacogenomics is likely to increase as the cost of drugs continues to rise.
